Excelsior Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
Excelsior Biopharma has a total shareholder equity of NT$1.0B and total debt of NT$110.0M, which brings its debt-to-equity ratio to 10.8%. Its total assets and total liabilities are NT$1.6B and NT$559.6M respectively.
Key information
10.8%
Debt to equity ratio
NT$110.00m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$326.85m |
| Equity | NT$1.02b |
| Total liabilities | NT$559.65m |
| Total assets | NT$1.58b |
Recent financial health updates
Recent updates
Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital
Apr 01
Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?
Mar 11Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?
Feb 09Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?
Jan 11
Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)
Dec 22Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative
Nov 30Financial Position Analysis
Short Term Liabilities: 6496's short term assets (NT$769.4M) exceed its short term liabilities (NT$183.3M).
Long Term Liabilities: 6496's short term assets (NT$769.4M) exceed its long term liabilities (NT$376.4M).
Debt to Equity History and Analysis
Debt Level: 6496 has more cash than its total debt.
Reducing Debt: 6496's debt to equity ratio has increased from 0% to 10.8% over the past 5 years.
Debt Coverage: 6496's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 6496's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 18:54 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Excelsior Biopharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsiu Chi Lin | Masterlink Securities Corp. |